Hypertension is an independent determinant of cardiovascular risk, a phenotype that usually has a strong genetic component. Neuropeptide Y (NPY) plays an important role in BP homeostasis. The aim of this study was to investigate the possible influence of NPY polymorphisms on hypertension in a South Indian population. A total of 252 subjects (132 controls and 120 hypertensives) were analysed for T1128C, G1258A and A7735G polymorphisms in the NPY gene. Body mass index (BMI), pulse, SBP and DBP were assessed. Direct sequencing of PCR products was adopted for genotyping. All three polymorphisms were found to be in Hardy-Weinberg equilibrium. Additive, dominant and recessive models were tested using multivariate regression analysis. The results of our study reveal a significant association between T1128C and hypertension even after adjusting for age, sex and BMI. The adjusted OR (95% confidence interval) for the recessive model was 0.56 (0.33-0.95). The other two polymorphic sites (G1258A and A7735G) are not associated with hypertension. The Pro7 allele of the T1128C polymorphic site-containing haplotype (CGA) is associated with hypertension (P ¼ 0.049), but the combined haplotypes did not show any evidence of haplotype-phenotype association (global P ¼ 0.129). These data support the hypothesis that hypertension is influenced by the NPY T1128C polymorphism.
Introduction
The aetiology of hypertension has been the subject of extensive research, as hypertension is considered a common risk factor for cardiovascular and renal diseases. The prevalence of hypertension is increasing faster in developing countries as compared with that in developed countries. 1 A multi-centre study revealed an upward trend in the prevalence of hypertension in India and Bangladesh. 2 Both genetic predisposition and environmental factors have been found to be associated with hypertension. Risk factors often correlated with hypertension include high fat intake, excessive consumption of alcohol, physical inactivity and psychosocial stresses. 3 The cardiovascular system is widely innervated both by sympathetic and capsaicin-sensitive sensory nerves, 4 which play significant roles in controlling the resistance vascular tone through the release of two classes of neurotransmitters such as vasoconstrictors and vasodilators.
Neuropeptide Y (NPY), a 36-amino-acid peptide, 5 is one of the most abundant neuropeptides in both the peripheral and central nervous systems. 6 In the central nervous system, NPY is purportedly involved in multiple tasks, for example, in the promotion of feeding, in anxiolysis and in modulating the release of a variety of hormones. 7 In the peripheral sympathetic nervous system, NPY, together with noradrenaline, 8 can mediate several cardiovascular effects, including vasoconstriction and modulation of transmitter release. 9 Age and hyperlipidaemia may also enhance vasoconstrictor responses to NPY. 10 An enhanced role of NPY has also been suggested in congestive heart failure. Furthermore, elevated levels of circulating NPY were reported in patients with cardiovascular disease such as acute myocardial infarction and angina pectoris.
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The NPY gene is located on chromosome-7q15.1. The gene is B8 kb in length and contains four exons. 12, 13 The NPY gene produces a precursor protein that includes a signal peptide, mature NPY and a C-terminal flanking peptide.
14 The Pro7 allele of T1128C has shown association with increased blood pressure (BP), 15 carotid atherosclerosis 16 and increased cholesterol levels and BP in obese subjects. 16, 17 Given the above information, we propose that the NPY gene is a candidate gene for hypertension. Few studies to date have examined the association between NPY polymorphisms and hypertension, and these studies are mainly restricted to the Dutch and Nordic populations. Therefore, we conducted a populationbased case-control study to determine the role of NPY gene polymorphisms in the progression of hypertension in a South Indian population.
Materials and methods

Subjects
A total of 252 adult individuals living in Kota were included in this study, recruited through a health check-up centre in the Nilgiris Adivasi Welfare Association (NAWA) health centre in 2006. NAWA is a tribal welfare organization working for the welfare and development of the scattered aboriginal tribes of Nilgiris in Tamil Nadu and adjoining areas by running hospitals, dispensaries and creches. In addition, subjects were recruited from among participants in other ongoing health-related research projects that did not involve the use of antihypertensive medication. As NAWA routinely conducts community health camps, nobody declined to participate, even without offers of monetary compensation. Recruitment efforts were specifically designed to recruit approximately equal numbers of women and men in the 3-month period.
A total of 120 subjects (58 men, 62 women) with hypertension either had systolic BP (SBP) of X140 mm Hg, diastolic BP (DBP) of X90 mm Hg (or both) or had taken antihypertensive drugs. The control subjects comprised a total of 132 individuals (57 men, 75 women) who had no history of hypertension, and their SBP and DBP were less than 140 mm Hg and less than 90 mm Hg, respectively. Based on a power analysis, these sample sizes were determined large enough to detect a significant odds ratio (OR) of 0.5, with a power of 73% and an alpha of 5%, and a minor allele frequency difference of 0.15 between cases and controls. A larger sample size of 150 or 200 cases and controls would increase the power of the study to 79 or 89%.
Any participant with congenital malformations of the heart or vessels and other diseases that cause secondary hypertension were excluded from the study. BP measurements were taken on the right arm with the subject seated. A standardized calibrated mercury column-type sphygmomanometer and appropriate-sized cuffs were used following standard procedures. 18 SBP and DBP values were recorded as the means of three readings taken at least 5 min apart. On the basis of the recorded BP measures, potential subjects were classified as control (BP o140/90 mm Hg) and hypertensives (BP 4140/ 90 mm Hg) according to the guidelines of the International Society of Hypertension Guidelines SubCommittee. 19 Following informed consent, venipuncture on each study subject was performed and a blood specimen was collected into an EDTA vaccutainer. Genomic DNA was extracted from all the participants, using standard proceduredescribed elsewhere. 20 This study was approved by the Institutional Review Board of the Center for Cellular and Molecular Biology, Hyderabad. Written informed consent was obtained from each participant.
NPY genotyping
Two NPY gene-specific primers were designed to amplify 516-and 417-bp PCR products covering exon-2 and exon-4, respectively (primer-I, forward:
0 ; and primer-II, forward: 5 0 -CCCGGTCATCTTTCACTTCAG-3 0 , reverse: 5 0 -GCGAAACGAACCCTGAATCTG-3 0 ). All single-nucleotide polymorphisms (SNPs) were analysed by PCR followed by sequencing. The PCR products were directly sequenced using the Big Dye Terminator Cycle Sequencing Ready Reaction kit and an ABI PRISM 3730 DNA Analyzer (Applied Biosystems, Foster City, CA, USA).
Statistical analysis
Baseline characteristics were compared between subjects with hypertension and controls by unpaired Student's t-test. Allele frequencies were estimated by the gene counting method and their distribution was tested for Hardy-Weinberg equilibrium by w 2 -test using the HWSIM programme. 21 The association between hypertension and each SNP was examined by multivariable logistic regression analysis, with adjustment for age, sex and body mass index (BMI), according to additive, dominant and recessive genetic models, and the P-value, OR and 95% confidence interval were calculated. All statistical analyses were performed with the SPSS statistical software version 16.0 (SPSS Inc., Chicago, IL, USA) for Windows. P ¼ 0.05 (twotailed) was considered statistically significant, and were further subjected to Bonferroni correction to account for multiple comparisons. The Haploview software with default setting was used to assess linkage disequilibrium between each pair of SNPs and also to define haplotype blocks. 22 To evaluate phenotypehaplotype association and to adjust the P-values with covariates we used the Hap-Clustering programme. 23 Power analysis was conducted using a Wald test-based approach for log OR implemented in R 2.5.0.
Results
The characteristics of control and hypertensive subjects are shown in Table 1 . BMI, SBP, DBP and pulse rate are significantly higher in the hypertensive group than in the control group. The distribu-tion of genotypes for T1128C (Leu7Pro; rs16139), G1258A (Ser50Ser; rs9785023) and A7735G (3 0 untranslated region; rs16475) polymorphisms along with their respective minor allele frequencies in the hypertensive and control subjects are reported in Table 2 . The observed genotype frequencies were found to be in Hardy-Weinberg equilibrium for each polymorphism in both cases and controls. These polymorphisms were further analysed for their potential association with hypertension.
Multivariable logistic regression analysis with adjustment for age, sex and BMI reveal that the T1128C polymorphism of the NPY gene (additive model and recessive model) is significantly associated with the prevalence of hypertension ( Table 2 ). The recessive model for T1128C compared the combined group of the CC and TC genotypes with individuals with the TT genotype. The adjusted OR (95% confidence interval) for the recessive model is 0.56 (0.33-0.95), and this association persists even after conservative Bonferroni correction (P ¼ 0.049). The other two SNPs of the NPY gene are not significantly associated in any model ( Table 2) . We did not find strong linkage disequilibrium between these SNPs, the low r 2 for every pair of SNPs indicates that these SNPs cannot be tagged by each other (T1128C-G1258A,
Haplotype analysis of these three variants in the hypertensive and control groups, with adjustment for age, sex and BMI, shows a marginal significance between the CGA (1128C-1258G-7735A) haplotype and hypertension (P ¼ 0.049), but the overall haplotype effect on hypertension is not significant (global P ¼ 0.129) ( Table 3) . 
Discussion
The present study examines the relationship of three NPY gene polymorphisms with hypertension in a South Indian population. BMI, SBP, DBP and pulse rate are significantly higher in the hypertensive group than in the control group. We found that the T1128C polymorphism at the NPY gene is significantly associated with hypertension, in both additive and recessive models. Both TC and the CC genotypes show increased risk for hypertension as compared with the TT genotype. We do not see a significant association between the other polymorphisms (G1258A, A7735G) and hypertension in this population. At the haplotype level, the NPY gene also shows a positive association between the haplotype containing the Pro7 allele (1128C) and hypertension. This T1128C polymorphism leads to substitution of Leu7 by Pro7 in the signal peptide sequence of preproNPY, thereby altering the synthesis, processing and release of the active peptide. Previous analysis of the entire coding region of the NPY gene in Finnish and Dutch non-diabetic obese subjects revealed a significant association between the T1128C polymorphism and high serum total cholesterol and low-density lipoprotein levels. 17 More recently, the T1128C polymorphism has been reported to be associated with type-2 diabetes, 16, 24 atherosclerosis 15 and coronary heart disease. 25 Furthermore, the NPY T1128C polymorphism has been reported to be associated with myocardial infarction and stroke in Swedish hypertensive patients. 26 This last study did not demonstrate an association of the Pro7 allele with common cardiovascular phenotypes such as BP, total cholesterol, low-density lipoprotein and high-density lipoprotein. However, in total, these studies suggest that the NPY T1128C polymorphism is a strong independent risk factor for various cardiovascular diseases. In contrast to these findings, no association between the NPY T1128C polymorphism and myocardial infarction was reported in a retrospective casecontrol study of a Japanese population. 27 To date, most, if not all, positive associations reported with the NPY gene polymorphism T1128C have been found largely in the Netherlands and some Nordic countries such as Finland and Sweden. 15, 25, 26 Irreproducibility of positive findings has been a common criticism levelled at association studies investigating the common genetic basis of complex diseases. 22 The frequency of the Pro7 allele has been reported to be 0.08 in Finns, 0.03 in Dutchmen 17 and virtually absent in Japanese 28, 29 and Koreans. 30 An extremely low frequency of Pro7 was observed in a Chinese population, 31 whereas Duan et al. 32 failed to detect this allele in the same region. Our previous study reports the presence of Pro7 across many Indian populations, with a wide variation of allele frequencies across ethnicities. 33 These results are consistent with physiological predictions, as the T1128C risk allele causes radical changes in the tertiary structure of the signal sequence of NPY 34 and exhibits higher synthesis, processing and release of the active peptide, 35 which has more vasoconstrictor property, 36 a leading disturbance in BP homeostasis. 37, 38 Limitations of the current study include small sample size and also focus on one ethnic group may limit the generalizability of findings to other ethnic groups. The inconsistencies between association studies may also reflect the complex interactions between multiple population-specific genetic and environmental factors. We recognize that any association study (even a case-control study) should be regarded as provisional and that replication in independent population studies is critical. The present study is population-based, involving a sample of relatively homogeneous genetic background, and therefore the results are unlikely to be affected by population stratification. In conclusion, the present study suggests that the NPY gene may contribute to increased risk for hypertension.
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